PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia

The document discussed the potential of PPAR-γ agonists, particularly pioglitazone, in treating primary cicatricial alopecia (PCA), with a focus on lichen planopilaris (LPP). PPAR-γ, a regulator of lipid metabolism and inflammation, was found to be downregulated in affected scalp areas, contributing to disease progression. Clinical trials showed mixed results, with some patients experiencing stabilization and hair regrowth, while others had adverse reactions leading to high dropout rates. The findings suggested that PPAR-γ agonists could modulate inflammation and fibrosis in PCA, but further large-scale, controlled trials were needed to confirm their efficacy and safety.